Another biotech startup runs into a PhII pileup in Parkinson's
GLP-1R agonists have become standard therapies in diabetes, with some proven weight loss features and a safety profile that promises to bring them into the mainstream as obesity drugs. But when Seulki Lee was at Johns Hopkins for a lengthy stretch as an associate professor, he and the noted neuroscientist Ted Dawson spent time investigating the anti-inflammatory side of the drug that they felt had real potential in treating neurodegenerative diseases like Alzheimer’s and Parkinson’s.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.